Gemcitabine Plus BCG Clears Bladder Cancer in 96% of Patients After BCG Failure

People who have early-stage bladder cancer that return after BCG, the next step can be challenging. Options are limited, and some patients are told to consider removing the bladder. A small study from Memorial Sloan Kettering Cancer Center, published in The Journal of Urology, suggests a change in how two familiar drugs are given may help. Patients received gemcitabine, a chemotherapy, alternating with BCG, an immune treatment. Both drugs went directly into the bladder. Six months later, the cancer was gone in 96% of them.

What Happens When Bladder Cancer Comes Back After BCG?

Most bladder cancers are found before they grow into the bladder muscle. These are called non-muscle-invasive bladder cancers. For high-grade cases, the standard treatment after surgery is BCG, a weakened bacteria placed into the bladder through a catheter to rouse the immune system against cancer cells.

BCG works for many people, but the cancer often returns. When it does, doctors may repeat BCG. Historically, a second round of BCG alone has cleared the cancer at six months in roughly half of patients, and those responses don't always last. If the cancer keeps returning, the conversation can turn to newer drugs or to removing the bladder, a major surgery that changes daily life.

How Does Gemcitabine Plus BCG Treatment Work?

Neither drug is new. Gemcitabine is a chemotherapy that stops cancer cells from copying their DNA, and it is already used in the bladder with few side effects. BCG has been a standard bladder treatment for decades.

What the researchers changed was how the two are combined. Over 10 weeks, patients received gemcitabine twice in weeks 1, 4, 7 and 10, and BCG once a week in the weeks in between, for 8 gemcitabine doses and 6 BCG doses in total. Both drugs were placed directly into the bladder through a catheter. The idea is that chemotherapy damages the cancer while BCG keeps the immune system working against it.

The study's main goal was to find the highest gemcitabine dose patients could safely tolerate. Doses started at 500 mg and rose to 2,000 mg, which became the recommended dose for future studies.

Gemcitabine-BCG Study Results: Response Rates and Side Effects

The study enrolled 25 patients with high-grade bladder cancer that had come back after earlier BCG treatment. Their median age was 68. About two-thirds (17 patients) had carcinoma in situ, a flat, fast-growing form that can be harder to treat.

Six months after starting treatment, 24 of the 25 patients (96%) had no sign of cancer in the bladder. Among those with carcinoma in situ, 16 of 17 (94%) responded. The researchers compared this with a historical response rate of about 50% for repeating BCG alone.

Urine tests also hinted at why the combination may work. During treatment, levels of immune signals that draw cancer-fighting T cells into the bladder went up, and levels of a signal that dampens the immune response went down.

Side effects were mostly mild, similar to what patients usually experience with either drug alone. No one had a serious (grade 3 or higher) treatment-related side effect. About 72% of patients had grade 1 side effects, the mildest level, and 20% had grade 2.

What Is the GAIN-BCG Phase 3 Bladder Cancer Trial?

The results are early, and the authors themselves say gemcitabine plus BCG should not yet replace repeat BCG outside a clinical trial. The study included only 25 patients at a single high-volume cancer center, and there was no comparison group receiving BCG alone. Biopsies after treatment weren't required, which may make the response rate look better than it is. Six months is also a short time for a cancer known for coming back, so the key question is how long these responses last.

That is what a new phase 3 trial is designed to answer. The trial, called GAIN-BCG (Alliance A032303), randomly assigns patients to gemcitabine plus BCG or to BCG alone. Its main goal is to see whether the combination keeps high-grade cancer from returning for longer. Adults whose non-muscle-invasive bladder cancer came back within two years of prior BCG may be eligible. The trial is enrolling at cancer centers across the United States, and it is listed on ClinicalTrials.gov as NCT07000084.

Questions to Ask Your Doctor About Bladder Cancer Treatment After BCG

If your bladder cancer has come back after BCG, these questions may help guide the conversation:

• Is my cancer considered BCG-exposed or BCG-unresponsive, and what options fit that situation?
• Could I be eligible for the GAIN-BCG trial or another clinical trial?
• What are the pros and cons of repeating BCG, adding gemcitabine, or trying a newer treatment?
• How often will I need cystoscopies to check whether the cancer has returned?

References

1. Gaffney C, et al. Phase I trial of intravesical gemcitabine and BCG (GemBCG) for BCG-exposed high-grade non-muscle-invasive bladder cancer. The Journal of Urology, Oct. 3 2026.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.